Inhibikase Therapeutics (NYSE:IKT) Research Coverage Started at LADENBURG THALM/SH SH

LADENBURG THALM/SH SH initiated coverage on shares of Inhibikase Therapeutics (NYSE:IKT) in a report released on Wednesday morning, Marketbeat reports. The brokerage issued a buy rating and a $4.00 price target on the stock.

A number of other equities research analysts also recently commented on IKT. Jefferies Financial Group reiterated a “buy” rating on shares of Inhibikase Therapeutics in a research report on Monday, December 29th. HC Wainwright restated a “buy” rating and issued a $8.00 target price on shares of Inhibikase Therapeutics in a report on Friday, December 26th. Bank of America started coverage on Inhibikase Therapeutics in a research report on Wednesday, January 21st. They set a “buy” rating and a $6.00 target price on the stock. Finally, Cantor Fitzgerald began coverage on Inhibikase Therapeutics in a research report on Thursday, December 11th. They issued an “overweight” rating and a $4.00 price target for the company. Five investment analysts have rated the stock with a Buy rating, According to data from MarketBeat, the stock presently has an average rating of “Buy” and a consensus target price of $5.50.

Inhibikase Therapeutics Price Performance

IKT stock opened at $1.88 on Wednesday. The firm has a market cap of $141.33 million, a PE ratio of -0.70 and a beta of 0.76. Inhibikase Therapeutics has a 12 month low of $1.33 and a 12 month high of $2.58. The firm has a 50 day simple moving average of $1.78 and a 200 day simple moving average of $1.67.

Hedge Funds Weigh In On Inhibikase Therapeutics

Several institutional investors and hedge funds have recently bought and sold shares of the business. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. acquired a new position in Inhibikase Therapeutics in the 2nd quarter valued at approximately $64,000. Invesco Ltd. acquired a new stake in shares of Inhibikase Therapeutics during the 2nd quarter valued at $60,000. JPMorgan Chase & Co. purchased a new position in shares of Inhibikase Therapeutics during the 2nd quarter valued at $56,000. Virtu Financial LLC grew its holdings in shares of Inhibikase Therapeutics by 70.1% during the 4th quarter. Virtu Financial LLC now owns 22,869 shares of the company’s stock valued at $47,000 after acquiring an additional 9,423 shares in the last quarter. Finally, XTX Topco Ltd acquired a new position in shares of Inhibikase Therapeutics in the fourth quarter worth $42,000. Hedge funds and other institutional investors own 3.81% of the company’s stock.

Inhibikase Therapeutics Company Profile

Inhibikase Therapeutics, Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of small-molecule kinase inhibitors for rare neurodegenerative diseases. Headquartered in New Haven, Connecticut, the company focuses on advancing therapies for central nervous system disorders with high unmet medical need. Its research platform targets key signaling pathways implicated in neuronal survival and degeneration.

The company’s lead investigational candidate, IKT-148009, is a brain-penetrant inhibitor of PDK1 and ABL kinases.